Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch
Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch
Contenido no disponible. Consulta la fuente original.
Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.